Cargando…

Host Cell Reactivation and Transcriptional Activation of Carboplatin-Modified BRCA1

The breast cancer susceptibility gene 1 (BRCA1) has been shown to maintain genomic stability through multiple functions in the regulation of DNA damage repair and transcription. Its translated BRCT (BRCA1 C-terminal domain) acts as a strong transcriptional activator. BRCA1 damaged by carboplatin tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ratanaphan, Adisorn, Canyuk, Bhutorn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964185/ https://www.ncbi.nlm.nih.gov/pubmed/24678242 http://dx.doi.org/10.4137/BCBCR.S14224

Ejemplares similares

A DNA Repair BRCA1 Estrogen Receptor and Targeted Therapy in Breast Cancer
por: Ratanaphan, Adisorn
Publicado: (2012)

In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein
por: Atipairin, Apichart, et al.
Publicado: (2011)

Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine
por: Nhukeaw, Tidarat, et al.
Publicado: (2014)

Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib
por: Hongthong, Khwanjira, et al.
Publicado: (2021)

Recognition Properties and Competitive Assays of a Dual Dopamine/Serotonin Selective Molecularly Imprinted Polymer
por: Suedee, Roongnapa, et al.
Publicado: (2008)

Altered DNA Binding and Amplification of Human Breast Cancer Suppressor Gene BRCA1 Induced by a Novel Antitumor Compound, [Ru(η(6)-p-phenylethacrynate)Cl(2)(pta)]
por: Chakree, Korawan, et al.
Publicado: (2012)

Association of HLA-B*51:01, HLA-B*55:01, CYP2C9*3, and Phenytoin-Induced Cutaneous Adverse Drug Reactions in the South Indian Tamil Population
por: John, Shobana, et al.
Publicado: (2021)

Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations
por: Garcia, Andrew, et al.
Publicado: (2019)

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
por: Vollebergh, Marieke A, et al.
Publicado: (2014)

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions
por: Moon, D H, et al.
Publicado: (2013)

A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)
por: Cortesi, L., et al.
Publicado: (2023)

Estrogen receptor transcription and transactivation: Genetic modifiers of cancer risks conferred by BRCA1 and BRCA2
por: Devilee, P
Publicado: (2001)

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
por: Isakoff, Steven J, et al.
Publicado: (2017)

An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
por: Chenevix-Trench, Georgia, et al.
Publicado: (2007)

Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families
por: Pouliot, Marie-Christine, et al.
Publicado: (2017)

Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2
por: Osorio, A, et al.
Publicado: (2011)

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2
por: Silvestri, Valentina, et al.
Publicado: (2016)

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)
por: Puhalla, Shannon L., et al.
Publicado: (2021)

Multifunctional transcription factor TFII-I is an activator of BRCA1 function
por: Tanikawa, M, et al.
Publicado: (2011)

Concerted Transcriptional Regulation by BRCA1 and COBRA1 in Breast Cancer Cells
por: Aiyar, Sarah E., et al.
Publicado: (2007)

Egr-1 regulates the transcription of the BRCA1 gene by etoposide
por: Shin, Soon Young, et al.
Publicado: (2013)

Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers
por: Benitez-Buelga, Carlos, et al.
Publicado: (2016)

Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
por: Osorio, A, et al.
Publicado: (2009)

Antitumor Activity of the Carboplatin-α-Cyclodextrin Adduct
por: Liu, Weiping, et al.
Publicado: (1997)

BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer
por: Lu, Lingeng, et al.
Publicado: (2019)

Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer
por: Shakir, Abdur R.
Publicado: (2014)

Endoplasmic Reticulum Stress Is Involved in the Response of Human Laryngeal Carcinoma Cells to Carboplatin but Is Absent in Carboplatin-Resistant Cells
por: Brozovic, Anamaria, et al.
Publicado: (2013)

Host-derived reactive oxygen species trigger activation of the Candida albicans transcription regulator Rtg1/3
por: Oneissi, Mazen, et al.
Publicado: (2023)

Ten modifiers of BRCA1 penetrance validated in a Norwegian series
por: Heramb, Cecilie, et al.
Publicado: (2015)

Characterization of a negative transcriptional element in the BRCA1 promoter
por: MacDonald, Gwen, et al.
Publicado: (2007)

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
por: Mulligan, Anna Marie, et al.
Publicado: (2011)

Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific
por: Chehade, Rania, et al.
Publicado: (2016)

Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5- fluorouracil in locally advanced nasopharyngeal carcinoma
por: Dechaphunkul, Tanadech, et al.
Publicado: (2011)

Identification of DBC1 as a transcriptional repressor for BRCA1
por: Hiraike, H, et al.
Publicado: (2010)

BRCA1 functions as a novel transcriptional cofactor in HIV-1 infection
por: Guendel, Irene, et al.
Publicado: (2015)

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
por: Hakkaart, Christopher, et al.
Publicado: (2022)

Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions
por: Ruggiero, Antonio, et al.
Publicado: (2017)

Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma
por: Lv, Xing, et al.
Publicado: (2016)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
por: Ayhan, Sevgi, et al.
Publicado: (2023)

Functional analyses of rare germline BRCA1 variants by transcriptional activation and homologous recombination repair assays
por: Bassi, Nicola, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qf3o39d2uu24k7r6cduauq0rou